Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2007 | Varian

{ "pageType": "news-article", "title": "Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2007", "articleDate": "July 25, 2007", "introText": "", "category": "Corporate and Financial Releases" }

Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2007

PALO ALTO, Calif., July 25 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today is reporting net earnings of $50 million ($0.39 per diluted share) for the third quarter of fiscal year 2007 versus net earnings in the year-ago quarter of $66 million ($0.49 per diluted share, which included a one-time $0.08 per diluted share tax benefit from repatriation of foreign earnings). Compared to the same period last fiscal year, third quarter revenues grew 7 percent to $424 million, net orders rose 13 percent to $499 million, and the quarter-ending backlog increased 21 percent to $1.6 billion.

"We achieved double-digit orders growth in our Oncology Systems business during the quarter," said Tim Guertin, president and CEO of Varian Medical Systems. "Company revenues grew as expected in line with customer-requested delivery dates and weak first-half orders for Oncology Systems. Operating profitability for the quarter was reduced in part by product and geographic mix shifts. In addition, planned investments in growth initiatives, including our proton therapy and security and inspection acquisitions, research and development, and our China expansion, impacted profitability."

The company generated nearly $40 million in cash flow from operations in the quarter and ended the period with $193 million in cash. During the quarter, $22 million was spent to acquire Bio-Imaging Research (BIR), a supplier of detectors and software for processing and analyzing X-ray images in security and inspection systems. Another $82 million was spent to repurchase 1.9 million shares of common stock, and, as of the end of the quarter, the company had one million shares remaining in a 4.5 million share repurchase authorization that extends through the end of this fiscal year.

Subsequent to the close of the quarter, Varian's Board of Directors authorized the company to repurchase up to an additional 12 million shares of its stock for a period beginning on July 30, 2007 and ending on December 31, 2008(1).

Oncology Systems

Oncology Systems' third quarter revenues totaled $338 million, up 2 percent from the third quarter of last fiscal year. This business recorded third quarter net orders of $411 million, up 10 percent from the same period last year with 14 percent growth in North America and 6 percent growth in international markets.

"Our orders growth rate suggests that we are extending our leadership in the deployment of products and technology for image-guided radiotherapy and radiosurgery," Guertin said. "Our On-Board ImagerĀ® accessory for image-guidance was included on virtually every high-energy machine ordered in North America and it is now included in more than 50 percent of international orders for high energy machines. Image guided treatments are well on the way to becoming the standard of care in radiotherapy and radiosurgery. As of the end of the quarter, more than 525 installations of our On-Board Imager accessory were complete or in progress."

"Weak first half orders and customer requested delivery schedules led to expected single digit revenue growth in Oncology Systems during the quarter," said Guertin. "Profitability was down primarily due to a product mix shift that impacted the gross margin. Planned higher investments in research and development for next generation products also reduced operating profits."

X-Ray Products

Revenues for the X-Ray Products business, including X-ray tubes and flat panel digital image detectors for filmless imaging, were $63 million for the third quarter, up 12 percent from the year-ago quarter. Net orders for the quarter were $58 million, down 3 percent from the same period last year due to a decision by some customers to reduce the number of days of flat panel inventory on hand.

"Our long-term growth strategies for this business are on track with new product developments and an increasing number of customers who are beginning to develop equipment for filmless X-ray imaging," Guertin said. "Strong demand for our high-power X-ray tubes contributed to growth in revenues and profitability for this business in the quarter."

Other Businesses

The company's Other category, comprised of the Security and Inspection Products business (including newly acquired BIR), the ACCEL proton therapy business, and the Ginzton Technology Center, reported combined third quarter revenues of $23 million, up $14 million from the total for the same period last fiscal year. Net orders for this category were $30 million, up $21 million from the year-ago period, as a result of strong growth in the security business, and $3 million of acquired backlog from BIR. The ACCEL business contributed modestly to order growth.

"For the second consecutive quarter, we had outstanding growth in net orders for Security and Inspection Products," said Guertin. "We are beginning to receive volume orders for these products and we are stepping up manufacturing to meet increased customer demand."

"With ACCEL, we are addressing the challenges of commercializing its advanced proton technology and building a new medical business," Guertin said. "Market interest in protons is high, but large proton projects have a very long selling cycle and we do not believe we will begin generating revenue from these systems until fiscal year 2009."


"For the full fiscal year 2007, we believe that total company revenues should increase by about 10 to 11 percent above the fiscal 2006 total," Guertin said. "Net earnings for fiscal year 2007, including ACCEL and BIR, should be about $1.79 per diluted share for fiscal year 2007.

"While we were pleased to see strong orders growth in the third quarter, given the flatness in Oncology Systems orders during the first half, we have elected to wait to see fourth quarter orders before giving revenue and earnings guidance for fiscal 2008," Guertin said. "We anticipate that required investments in several new growth initiatives, including the integration and commercialization of the ACCEL proton therapy business, will stretch into fiscal 2008. As it stands, the ACCEL acquisition is likely to continue to be dilutive to earnings by about $0.02 per quarter through fiscal year 2008."

Investor Conference Call

Varian Medical Systems is scheduled to conduct its third quarter fiscal year 2007 conference call at 2 p.m. PT today. To hear a live webcast or replay of the call, visit the investor relations page under "About Varian" on the company's web site at where it will be archived for a year. To access the call via telephone, dial 1-866-543-6407 from inside the U.S. or 1-617-213-8898 from outside the U.S. and enter confirmation code 92205993. The replay can be accessed by dialing 1-888-286-8010 from inside the U.S or 1-617-801-6888 from outside the U.S. and entering confirmation code 60700450. The telephone replay will be available through 5 p.m. PT, Friday, July 27, 2007.

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,400 people who are located at manufacturing sites in North America and Europe and approximately 60 sales and support offices around the world. For more information, visit

Note 1:

Stock repurchases will be made in the open market, in privately negotiated transactions, or in structured Rule 10b5-1share repurchase plans, and may be made from time to time or in one or more larger repurchases. The program will be conducted in compliance with the SEC's Rule 10b-18 and applicable legal requirements and the timing of the repurchases and the number of shares to be repurchased at any given time will depend on market conditions, SEC regulations and other factors. The program does not obligate the Company to acquire any particular amount of common stock and the program may be modified or suspended at any time at the Company's discretion.

Forward-Looking Statements

Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including market acceptance of or transition to new products or technology such as image-guided radiation therapy (IGRT), stereotactic radiosurgery, filmless X-rays, proton therapy, and security and inspection; growth drivers; the company's orders, revenues, backlog, or earnings growth; future financial results and any statements using the terms "should," "believe," "suggests," "becoming," "anticipate," "is likely," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include demand for the company's products; the company's ability to develop and commercialize new products; the company's ability to meet demand for manufacturing capacity; the company's reliance on sole or limited-source suppliers; the company's ability to maintain or increase operating margins; the impact of competitive products and pricing; the effect of economic conditions and currency exchange rates; the effect of changes in accounting principles; the company's ability to meet Food and Drug Administration and other regulatory requirements for product clearances or to comply with Food and Drug Administration and other regulatory regulations or procedures; the possibility that material product liability claims could harm future revenues or require the company to pay uninsured claims; the effect of environmental claims and expenses; the company's ability to protect the company's intellectual property; the impact of reduced or limited demand by sole purchasers of certain X-ray tubes; the impact of managed care initiatives, other health care reforms, and/or third-party reimbursement levels on capital expenditures for cancer care; the potential loss of key distributors or key personnel; consolidation in the X-ray tubes market; the ability to make strategic acquisitions and to successfully integrate the acquired operations into the company's business; the risk of operations interruptions due to terrorism, disease (such as Severe Acute Respiratory Syndrome and Avian Influenza) or other events beyond the company's control; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

A summary of earnings and other financial information follows.

            Varian Medical Systems, Inc. and Subsidiary Companies
               Consolidated Statements of Earnings (Unaudited)

  (Dollars and shares
    in millions, except
    per share amounts)   Q3 QTR       Q3 QTR       Q3 YTD       Q3 YTD
                          2007         2006         2007         2006

  Net orders              $498.9        443.3      1,435.1      1,274.4
    Oncology Systems       410.9        373.9      1,113.7      1,065.3
    X-Ray Products          58.4         60.5        193.4        173.9
    Other                   29.6          8.9        128.0         35.2

  Order backlog         $1,581.6      1,309.6      1,581.6      1,309.6

  Revenues                $423.7        395.7      1,254.2      1,143.8
    Oncology Systems       337.7        330.5      1,012.6        953.3
    X-Ray Products          63.3         56.4        191.2        169.3
    Other                   22.7          8.8         50.4         21.2

  Cost of revenues (1)    $253.2        233.1        738.4        671.3

  Gross margin             170.5        162.6        515.8        472.5
    As a percent of
     revenues              40.2%        41.1%        41.1%        41.3%

  Operating expenses
    Research and
     development (1)        29.2         25.5         84.6         72.7
    Selling, general and
     administrative (1)     75.2         64.4        208.6        187.8

  Operating earnings        66.1         72.7        222.6        212.0
    As a percent of
     revenues              15.6%        18.4%        17.7%        18.5%

  Interest income, net       1.6          2.6          6.1          6.8

  Earnings before taxes     67.7         75.3        228.7        218.8

  Taxes on earnings (1)     17.4          9.6         67.9         56.1

  Net earnings (1)         $50.3         65.7        160.8        162.7

      Net earnings
       per share
       - basic: (1)        $0.40         0.50         1.26         1.24

      Net earnings
       per share
       - diluted: (1)      $0.39         0.49         1.22         1.20

  Shares used in the
   calculation of net
   earnings per share:
    Average shares
     outstanding - basic   127.0        131.1        128.1        131.3
    Average shares
     outstanding - diluted 129.9        135.3        131.4        135.9

  (1) Includes amounts for total share-based compensation expense and its
      related tax benefits and in 2006 a tax benefit related to the
      repatriation of foreign earnings.
      (in millions, except per share amounts)

                           Q3 QTR       Q3 QTR       Q3 YTD       Q3 YTD
                            2007         2006         2007         2006

  Costs of revenues         $2.0          1.8          6.0          4.8
  Research & development     1.2          1.1          3.8          3.2
  Selling, general &
   administrative            7.6          7.4         24.0         22.0
  Total                     10.8         10.3         33.8         30.0
  Taxes on earnings -
   SFAS 123R                (3.7)        (3.4)       (11.5)       (10.3)
  Taxes on earnings -
   repatriation               --        (10.2)          --        (10.2)
  Net earnings              $7.1         (3.3)        22.3          9.5

  Net earnings per diluted
   share - share-based
   compensation expense
   and repatriation of
   foreign earnings        $0.05        (0.03)        0.17         0.06

  Net earnings per diluted
   share - excluding
   compensation expense
   and repatriation
   of foreign earnings     $0.44         0.46         1.39         1.26

                Varian Medical Systems, Inc. and Subsidiaries
                    Condensed Consolidated Balance Sheets

  (In thousands)                                  June 29,     September 29,
                                                    2007           2006

  Current assets
    Cash and cash equivalents                     $192,790       $272,508
    Short-term marketable securities                    --         93,599
    Accounts receivable, net                       431,479        471,820
    Inventories                                    276,048        189,653
    Deferred tax assets and other                  159,989        128,469
      Total current assets                       1,060,306      1,156,049

  Property, plant and equipment                    368,363        319,028
    Accumulated depreciation and amortization     (211,543)      (188,710)
      Property, plant and equipment, net           156,820        130,318

  Goodwill                                         170,184        121,389
  Other assets                                     142,243        103,995
  Total assets                                  $1,529,553     $1,511,751

  Liabilities and Stockholders' Equity
  Current liabilities
    Accounts payable                               $82,042        $77,985
    Accrued expenses                               249,148        265,750
    Deferred revenues                               92,492        117,813
    Product warranty                                48,528         42,992
    Advance payments from customers                175,037        131,462
    Current maturities of long-term debt             8,966          7,954
      Total current liabilities                    656,213        643,956
  Other long-term liabilities                       27,205         21,186
  Long-term debt                                    40,443         49,356
      Total liabilities                            723,861        714,498

  Stockholders' Equity
  Common stock                                     126,416        129,721
  Capital in excess of par value                   302,091        265,214
  Retained earnings and accumulated other
   comprehensive loss                              377,185        402,318
      Total stockholders' equity                   805,692        797,253
  Total liabilities and stockholders' equity    $1,529,553     $1,511,751

  Elisha Finney (650) 424-6803

  Spencer Sias (650) 424-5782

SOURCE: Varian Medical Systems, Inc.

CONTACT: Elisha Finney, +1-650-424-6803,, or
Spencer Sias, +1-650-424-5782,, both of Varian Medical
Systems, Inc.

Web site: